DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cancer stem cells (CSCs) drive tumor initiation, recurrence, and drug resistance.
• DAB2IP, a Ras-GTPase activating protein, is frequently lost in various cancers.
• The role of DAB2IP in regulating CSC properties remains largely unexplored.

Purpose of the Study:

• To investigate the role of DAB2IP in the regulation of cancer stem cell properties.
• To elucidate the molecular mechanisms by which DAB2IP loss influences CSC phenotypes.
• To explore the therapeutic potential of targeting the DAB2IP-mediated pathway in cancer.

Main Methods:

• Analysis of DAB2IP expression in relation to CSC markers.
• Investigation of DAB2IP interaction with c-kit gene regulatory elements.
• Utilizing in vitro and in vivo models, including DAB2IP knockout mice.
• Examination of the c-kit-PI3K-Akt-mTOR-c-myc-ZEB1 signaling axis.

Main Results:

• Loss of DAB2IP is associated with enhanced CSC properties.
• DAB2IP suppresses c-kit (CD117) gene expression via interaction with a novel silencer.
• DAB2IP inhibits the c-kit-PI3K-Akt-mTOR pathway, reducing c-myc and ZEB1 expression.
• Inverse correlation between DAB2IP and CD117/ZEB1 observed in clinical samples and mouse models.

Conclusions:

• DAB2IP plays a critical role in suppressing CSC phenotypes.
• The CD117-mediated ZEB1 signaling pathway is a key mechanism regulated by DAB2IP.
• Restoring DAB2IP function or targeting this pathway may offer therapeutic strategies against CSCs.